Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3681390 | 0.98 | HTR2C (0.66) | HTR2CHDAC1HDAC8HDAC6KDM1A | |
| SCHEMBL2539686 | 0.95 | HTR2C (0.68) | HTR2CHDAC1HDAC8HDAC6KDM1A | |
| SCHEMBL23817068 | 0.92 | HTR2C (0.59) | HTR2CKDM1AKMT2A | |
| SCHEMBL1847401 | 0.91 | HTR2C (0.73) | HTR2CKDM1A | |
| SCHEMBL26154113 | 0.89 | HTR2C (0.56) | HTR2CHDAC1HDAC8HDAC6KDM1A | |
| SCHEMBL8767842 | 0.89 | HTR2C (0.56) | HTR2CHDAC1HDAC8HDAC6KDM1A | |
| SCHEMBL23059786 | 0.87 | HTR2C (0.54) | HTR2CHDAC1HDAC8HDAC6KDM1A | |
| SCHEMBL20618447 | 0.86 | HTR2C (0.58) | HTR2CKDM1APPARDMEN1KMT2A | |
| Cyanide SCHEMBL27770959 | 0.84 | HTR2C (0.66) | HTR2CKDM1AMEN1KMT2AKDM4E | |
| SCHEMBL12328269 | 0.83 | HTR2C (0.50) | HTR2CKDM1APPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023097233-A1 | SPIROCYCLIC CYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | Shenzhen Bay Laboratory (CN) | 2023-05-25 | — | — | US | disclosed |
| CN-110730767-B | Process for producing cycloalkyl (trifluoromethyl) benzene | 东丽精细化工株式会社 | 2022-06-24 | — | — | CN | disclosed |
| US-11066422-B2 | Method of producing cycloalkyl(trifluoromethyl)benzene | TORAY FINE CHEMICALS CO., LTD. (JP) | 2021-07-20 | — | — | US | disclosed |
| US-20210053992-A1 | METHOD OF PRODUCING CYCLOALKYL(TRIFLUOROMETHYL)BENZENE | TORAY FINE CHEMICALS CO., LTD. (JP) | 2021-02-25 | — | — | US | disclosed |
| EP-3653594-A1 | PRODUCTION METHOD FOR CYCLOALKYL(TRIFLUOROMETHYL)BENZENE | Toray Fine Chemicals Co., Ltd. (JP) | 2020-05-20 | — | — | EP | disclosed |
| CN-110730767-A | Process for producing cycloalkyl (trifluoromethyl) benzene | 东丽精细化工株式会社 | 2020-01-24 | — | — | CN | disclosed |
| US-20170327503-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2017-11-16 | — | — | US | disclosed |
| US-20070299072-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | SSB, EBNA1BP2, PML | HTR2C 4854/4885HDAC1 346/4885HDAC8 186/4885 |
| US-20070299072-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | KCNA5, KCNH1, KCNK5 | HTR2C 3081/4885HDAC1 390/4885HDAC8 434/4885 |
| US-11066422-B2 | Method of producing cycloalkyl(trifluoromethyl)benzene | HCN4, MAP2K4, GRHPR | HTR2C 3175/4885HDAC1 2135/4885HDAC8 1762/4885 |
| US-20210053992-A1 | METHOD OF PRODUCING CYCLOALKYL(TRIFLUOROMETHYL)BENZENE | HCN4, MAP2K4, GRHPR | HTR2C 3175/4885HDAC1 2135/4885HDAC8 1762/4885 |
| US-20170327503-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | PPARD, PPARG, RORC | HTR2C 3076/4885HDAC1 540/4885HDAC8 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.